Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).

NCT05720130 is registered in ClinicalTrials.gov with AdvanCell Pty Limited as lead sponsor.

NCT NCT05720130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05720130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
Lead sponsor
AdvanCell Pty Limited
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 15, 2023
Completion date
June 1, 2029
Enrollment
100 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer, metastatic hormone sensitive prostate cancer, prostate cancer